埃萬(wàn)妥單抗破局EGFR-TKI耐藥困境，在EGFR突變NSCLC治療領(lǐng)域展現(xiàn)廣闊前景。

*以下內(nèi)容僅供醫(yī)療衛(wèi)生專業(yè)人士瀏覽。

參考文獻(xiàn)：

[1]Westover D, Zugazagoitia J, Cho BC, et al. Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Ann Oncol, 2018, 29(suppl_1): i10-i19.

[2] Liao X, He T, Wan X, et al. Clinical management in NSCLC patients with EGFR mutation after osimertinib progression with unknown resistance mechanisms[J]. The Clinical Respiratory Journal, 2024, 18(10): e70025.

[3] Alissa J. C, Lecia V. S & Jessica J. L.Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management.Nature Reviews Clinical Oncology, 2022.

[4] Cho BC, Lu S et al. MARIPOSA Investigators. Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC. N Engl J Med. 2024 Jun 26.

[5]Passaro A, et al. Amivantamab plus chemotherapy (with or without lazertinib) vs chemotherapy in EGFR-mutated advanced NSCLC after progression on osimertinib: MARIPOSA-2, a phase III, global, randomized, controlled trial. ESMO Congress 2023, LBA15.

[6]Shirish MG, Byoung CC, Lu S, et al. Amivantamab Plus Lazertinib vs Osimertinib in First-line EGFR-mutant Advanced NSCLC: Longer Follow-up of the MARIPOSA Study. 2024 WCLC. OA.02.03.

[7] Chen ACC, Mok FST, Wong WKY, et al. Pattern of failure, impact of local therapy, and characteristics of long-term responders with advanced EGFR mutation positive non-small cell lung cancer treated with first-line osimertinib. Lung Cancer. 2025 Nov 1;210:108808.

[8] ShihJ, Wang J, Wang Y, et al. Amivantamab plus chemotherapy vs chemotherapy among Asian patients with EGFR-mutant advanced NSCLC after progression on osimertinib: A MARIPOSA-2 subgroup analysis. 2023 ESMO Asia. LBA11.

[9]S. Popat, K.L. Reckamp, R. Califano, et al. Amivantamab plus chemotherapy vs chemotherapy in EGFR-mutated, advanced non-small cell lung cancer after disease progression on osimertinib: Second interim overall survival from MARIPOSA-2. ESMO 2024. Abstract LBA54.

[10] Zhao W, Zhou W, Rong L, et al. Epidermal growth factor receptor mutations and brain metastases in non-small cell lung cancer. Front Oncol. 2022. 12: 912505.

[11] Califano R, Passaro A, Tan JL, et al. Amivantamab plus chemotherapy vs chemotherapy in EGFR-mutant advanced NSCLC after disease progression on osimertinib: Outcomes by osimertinib resistance mechanisms in MARIPOSA-2. 2025 ASCO. Abstract 8639.

審批編碼：CP-556189

批準(zhǔn)分發(fā)日期：12/10/2025

有效期：12/10/2026

*“醫(yī)學(xué)界”力求所發(fā)表內(nèi)容專業(yè)、可靠，但不對(duì)內(nèi)容的準(zhǔn)確性做出承諾；請(qǐng)相關(guān)各方在采用或以此作為決策依據(jù)時(shí)另行核查。